Malignant tumor is one of the principle diseases which threatens the health of human being, and its incidence rate has been dramatically increased in recent years.Modern medical model has transformed from biomedical model to the model of "biology-psychology-society",from experience-based medicine to evidence-based medicine (EBM).At the same time,individualization is also one of important principles of tumor combined therapy.EBM and individualization treatment are not to opposed to each other but to complement each other. This article expounded the relationship of EBM and individualization treatment in tumor therapy,and showed that both of these two principles must be grasped arid carried out in clinical work.

Objective To generate cytokine induced killer (CIK) by inducing lymphocytes cells from peripheral blood in vitro , and to study the phenotype and biological activities of CIK. Methods Lymphocytes cells were isolated fresh from peripheral blood of healthy donors by Ficoll Hypaque density centrifugation, and the cells obtained were resuspended in RPMI medium consisting of 10% fetal calf serum at 37℃, 5%CO 2 for 2h. On day 0, the nonadherent cells were activated with IFN ? (1 000U/ml) and the following days were stimulated with CD3mAb (3 75?g/ml) and rhIL 2 (600U/ml). Phenotype of CIK were analysed by FACS. The proliferation of CIK was tested using 3 H Thymidine, and the killing experiment using MTT tests. Results The proliferation peak of CIK was at day 20, and declined at day 30. The percentages of the cytotoxicity of CIK cells for stomach cancer cell line MGC803 and liver cancer cell line Bel7402 was 65 45%?5 68% and 68 37%?3 93% respectively. CIK cells expressed the phenotypes of CD3CD56, CD3, CD54, CD28CD54, CD11a, HLA DR and CD28. Conclusion IFN ?, CD3mAb and rhIL 2 can induce strong proliferation of peripheral lymphocytes to produce CIK cells expressing the phenotype of CD3CD56, CD3, CD54, CD28CD54, CD11a, HLA DR, CD28, which have strong cytotoxicity on tumor cells.

Biochemotherapy refers to the combination of biotherapy and chemotherapy,and it has been rapidly developed since its emergence.Biochemotherapy has brought both new therapies and new therapeutic ideas for the treatment of malignant tumors.In this article,we reviewed the recent advances in tumor biochemotherapies,including expansion of the indications,retaining of therapy even when tumor progressed(unique to biochemotherapy),and reversal of chemotherapy resistance by targeted therapy,the predicting response to tumor biochemotherapy,recent clinical trials of immunotherapy-based chemotherapy,and evaluation criteria for assessment of biochemotherapy response,and so on.

Objective To compare the effectiveness of nose jejunal tube (NJT) and nasogastric tube (NGT) in providing early enteral nutrition for patients with severe craniocerebral injury. Methods Forty patients with severe craniocerebral injury and required early enteral nutrition were equally and randomly divided into NJT group and NGT group based on the tube type. The biochemical indicators, gastrointestinal tract tolerance, and complications were compared between these two groups. Results Serum albumin, blood glucose, and lymphocyte count were not significantly different between these two groups before and immediately after nutritional support (all P ＞0. 05). However, 14 days after nutritional support, the blood sugar level significantly decreased compared with the baseline levels in the NJT group (P =0. 0001). The incidences of reflux (P = 0. 001) and abdominal distension (P =0.011) were significantly lower in NJT group than in NGT group. Conclusion NJT is superior to NGT in providing early enteral nutrition for patients with severe craniocerebral injury.

Objective　To investigate dynamic changes of the p53 gene and its protein during occurrence and metastasis of colorectal cancer and explore the relationship between p53 mutation and survival of the patients. Methods　p53 gene (exon 5-9) was examined by PCR, denaturing gradient gel electrophoresis (DGGE) and automated sequencing. Results　p53 alterations were found in exons 5 through 9 in 26 of the 41 patients (63%). Of the 26 patients, 6 had the alterations in the liver metastatic lesions but not in the original colorectal lesion. The other 20 had the alterations in both of the primary colorectal and hepatic metastatic lesions. Meanwhile, an additional mutation in the metastatic lesions was found in 3 cases. The analysis about the survival revealed that the patients with mutant p53 in the metastatic lesions had a longer survival as compared with those with wild type p53. Conclusion　In the process of liver metastasis of the colorectal cancer, p53 mutations mainly start in the primary colorectal lesion and then is kept and brought into the liver. It also might start from metastatic lesion in a few cases. For the patients who had liver metastasis of colorectal cancer and underwent hepatectomy, the survival is longer in mutant p53 group than in wild type p53 group.

In recent years, more and more people has suffered from cancer which are causing more and more death. According to evidence-based medicine, the individualized therapy and normalized therapy are important principles of tumor therapy now.In order to improve the quality and effect of tumor therapy, produce qualified oncology physicians, it is important to emphasis the training of oncologist physicians. This article, gives some advices in enhance the level of oncology physicians.

OBJECTIVE:To establish a method for simultaneous determination of notoginsenoside R1,ginsenoside Rg1 and gin-senoside Rb1 in Shenqi xinshu capsule. METHODS:HPLC was performed on the column of Zorbax SB-C18(150 × 4.6 mm,5 μm) with mobile phase of acetonitrile-water at a flow rate of 1.0 ml/min,detection wavelength was 203 nm,column temperature was 30℃,and the injection volume was 10 μl. RESULTS:The linear range was 0.199 8-3.996 0 μg for notoginsenoside R1,0.842 8-10.143 0 μg for ginsenoside Rg1 and 0.823 4-9.978 0 μg for ginsenoside Rb1;RSDs of precision,stability and reproducibility tests were low-er than 2%;recoveries were 95.17%-100.17%(RSD=1.81%,n=9),97.32%-101.18%(RSD=1.44%,n=9)and 95.22%-98.89%(RSD=1.22%,n=9). CONCLUSIONS:The method is simple,accurate and reproducible,and can be used for the simultaneous contents determination of notoginsenoside R1,ginsenoside Rg1 and ginsenoside Rb1 in Shenqi xinshu capsule.

The morbidity and mortality of malignant tumor is increasing in our country.It is crucial to enhance the clinical oncology education.We set the clinical oncology class for the medical university students and obtained good teaching effect by enhancing cognition,selecting the proper teaching content,making reasonable teaching program and using multiple teaching style.

Objective To evaluate the effect and adverse effect of combination chemotherapy with xeloda and oxaliplatin in advanced colorectal cancer. Methods 25 patients were treated with oral xeloda 1 250mg/m~2, administered twice daily from day 1 to day 14, and oxaliplatin 130mg/m~2/d iv on day 1.The regime was repeated every 21 days for at least 2 consecutive cycles. Result The results of evaluation of effectiveness of the reginme were as follow: 0 CR,12 PR,10 SD and 3 PD. The overall effective rate was 48%(12/25), the effective rate for patients who received the treatment primarily was 100%(3/3), and that of the patients who received the treatment for the secona time was 41%(9/22).Xeloda combined with oxaliplatin was well tolerated. The most common treatment-related adverse events with hand-foot syndrome in 40% (10/25) of patients, skin pigmentation in 68% (17/25), anorexia in 40% (10/25) of patients. Suppression of hematopoiesis, neurotoxicity, nausea and vomiting were mild. Conclusion The combined chemo-therapy with xeloda and oxaliplatin has a high therapeutic response with acceptable toxicity in patients with advanced colorectal cancer, and which was convenient to administer, with definite efficacy, and it could be extensively used, especially in elderly patients and outpatients.

Objective To investigate the possibility of using 5-aminolevulinic acid(5-ALA)induced protoporphyrin IX(PpIX)for photodynamic therapy(PDT)of nasopharyngeal carcinoma(NPC)cell line CNE2 cultured in vitro.Methods CNE2 cells cultured were incubated in a medium containing various concentrations of 5-ALA(0.01,0.05,0.1,0.25,0.5,1.0,2.0,4.0mmol/L)for 6 hours,then illuminated with different light doses(20,10,5,2J/cm2)using a semiconductor laser at 630nm.After 6,12,24 hours incubation with 5-ALA-PDT,the survival rates of CNE2 cells were analyzed by MTT assay.Results 5-ALA-PDT may effectively kill the CNE2 cells.The killing degree was positively correlated with the incubation time after irradiation,concentration of 5-ALA and the dosage of radiation(P